**Company Profile**

**Industry Sector:** Biotech

**Overview:** Aronora is a biotechnology company established for the commercialization of proprietary anticoagulant (“blood thinning”) products that do not cause bleeding.

**Target Markets:** Worldwide market for drugs that prevent or treat thrombotic vascular disorders is over $40 billion per year. Their limited safety is a significant obstacle to their efficient and safe use. E-WE Thrombin is intended to provide a safe alternative to current drugs in acute ischemic stroke and heart disease (>2M patients per year in the US), with an estimated market potential exceeding $10 billion per year. XISOMAB and AXIMAB are intended to provide safe anticoagulation during septic related coagulopathy and to limit venous thrombosis, respectively. The current market leaders for these indications (Xigris® and Lovenox®) generate over $4 billion in revenue annually, even though only a subset of patients receive these drugs due to bleeding side-effects. (*Xigris® has recently been withdrawn from the market)*

**Management**

**Andras Gruber, M.D. President/CEO**
Dr. Gruber is General Manager and Co-Founder of Aronora, Inc. and is an Associate Professor of Biomedical Engineering and Medicine at Oregon Health & Science University (OHSU), and adjunct faculty at The Scripps Research Institute and the Oregon National Primate Research Center. He has clinical, academic research, and pharma industry management experience.

**Erik I. Tucker, Ph.D. Vice President/COO**
Dr. Tucker has directed all R&D operations since 2009, advancing Aronora’s exciting product candidates towards clinical testing and ultimate FDA approval. Dr. Tucker is a Co-Founder of Aronora, Inc. and the Primary Investigator on several NIH and Bayer Healthcare funded projects to develop E-WE Thrombin, XISOMAB, and AXIMAB.

**Key Value Drivers**

**Technology:** The lead product candidate is an injectable anticoagulant biologic agent, recombinant **E-WE Thrombin**, a bioengineered protein C activator enzyme that inhibits blood clotting only inside blood vessels. The first batch of manufactured cGMP-grade E-WE Thrombin will enter pre-IND toxicology evaluation in early 2012.

**Competitive Advantage**

**Direct competition:** All current anticoagulant drugs cause bleeding and are not safe at their effective doses.

**Our product candidates:** 1) No bleeding or other side effects. 2) Antithrombotic efficacy in large primates at lower doses than market leaders.

**Plan & Strategy:** Unlike typical start-up biotech companies, Aronora develops product candidates only if they have already demonstrated safety and efficacy in large primates. The company intends to develop both E-WE Thrombin, AXIMAB, and XISOMAB to phase 1/2 clinical stage and then secure a strategic alliance or acquisition.

**Product Pipeline**

<table>
<thead>
<tr>
<th>Product</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-WE Thrombin (AB002): stroke, heart attack</td>
<td>Preclinical</td>
<td>Clinical Phase I</td>
<td></td>
</tr>
<tr>
<td>AXIMAB (AB012): venous thrombosis</td>
<td>Preclinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XISOMAB (AB022): sepsis</td>
<td>Preclinical</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

쥐